Myriad Genetics launches new molecular diagnostic product

Myriad Genetics, a developer of molecular diagnostic and therapeutic products, has launched OnDose, the company’s seventh molecular diagnostic product.

According to Myriad Genetics, OnDose utilizes a technology to measure a patient’s exposure to the chemotherapy drug, 5-Fluorouracil (5-FU), to help oncologists adjust and optimize dosing to maximize efficacy and reduce toxicity.

OnDose provides ongoing insight to help the physician proactively adjust and optimize dosing to maximize efficacy and reduce toxicity, and allows physicians to make a pharmacokinetic determination of the area under the curve (AUC) for each infusion cycle, the company said.

Studies have shown that 5-FU dosing based on pharmacokinetic determination of the AUC versus using standard body surface area dosing allows better optimization of treatment in patients receiving 5-FU infusion therapy, the company added.

The price of OnDose is $300 for each AUC determination. OnDose will be sold through Myriad’s 150-person oncology sales force.

Gregory Critchfield, president of Myriad Genetics Laboratories, said: With the launch of OnDose, Myriad is the only laboratory where full genotypic and phenotypic analysis can be obtained to help optimize 5-FU dosing for patients.

This is good news for doctors who will have better tools to help optimize treatment, for payers saving downstream healthcare costs, and especially for patients whose cancers may now be more effectively treated with lower toxicity.